Investment
Features
FeesSafety
Academy
More
Pluang+

Nicola Mining starts 2026 drilling at Treasure Mountain to explore high-grade silver-lead-zinc veins.

Market News
18 Sep 2026
Newsfile Corp
View Source
Bullish
Nicola Mining starts 2026 drilling at Treasure Mountain to explore high-grade silver-lead-zinc veins.

Nicola Mining has launched its 2026 exploration drilling program at Treasure Mountain, a permitted silver mine in British Columbia that has been on care since 2013. The program targets the MB Zone, a previously undrilled area with promising surface mineralization including silver, lead, zinc, copper, and gold. Four drill holes totaling about 800 meters will test the continuity and depth of mineralized veins, with results expected by year-end. Positive findings could significantly advance Nicola's understanding and future exploration plans for Treasure Mountain.

Nicola Mining's new drilling program at Treasure Mountain provides context for readers following mining developments. For readers following Basic Materials-sector stocks on Pluang, here is the market snapshot as of Sep 18, 2026 19:13 WIB: Among 34 priced US stocks, 20 rose and 13 fell. Notable movers include Barrick Gold Corp (B) at USD 43.97 with a 1-day change of +0.65% and a typical hold time of 54 days, MP Materials (MP) at USD 49.69 up +0.63% with strong buy interest (83% buy orders), and Rio Tinto (RIO) at USD 97.47 down -0.58% with a typical hold time of 3 days.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Apple stock could hit $450 by 2027 driven by AI, strong iPhone growth, and services expansion.

Apple stock could hit $450 by 2027 driven by AI, strong iPhone growth, and services expansion.

Apple reported strong Q3 results with $109.42 billion revenue and its ninth consecutive earnings beat, driven by 22% iPhone growth. Despite a 23% stock rise this year, shares trade below potential value due to margin concerns and supply constraints. ...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App